BUZZ-<a href="https://laohu8.com/S/TEM">Tempus AI</a> climbs on $1.1 billion contract value** Shares of genetics-testing firm Tempus AI TEM.O up 10.4% at $73.19 premarket
** Reports record total contract value of over $1.1 bln and net revenue retention of ~126%
** Says it signed data agreements with more than 70 customers in 2025, including AstraZeneca AZN.L, Pfizer PFE.N, Merck MRK.N and other major drugmakers
** Co says engagement with life sciences firms at "record levels," giving visibility to continued growth in 2026 and beyond
** Preliminary 2025 data & applications revenue estimated at $316 mln, up ~31% YoY
** Says FY prelim 2025 revenue about $1.27 billion, up roughly 83%
** TEM stock gained ~76% over the past year
(Reporting by Tharuniyaa Lakshmi in Bengaluru)
((tharuniyaa@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.